Research programme: familial dysautonomia therapeutic lentivirus - Americal Gene Technologies

Drug Profile

Research programme: familial dysautonomia therapeutic lentivirus - Americal Gene Technologies

Alternative Names: AG IKAP; AG-IKAP - Familial dysautonomia therapeutic lentivirus

Latest Information Update: 22 Mar 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator American Gene Technologies International
  • Developer American Gene Technologies International; Montana State University
  • Class Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Peripheral nervous system diseases

Most Recent Events

  • 13 Mar 2018 American Gene Technologies International has patent protection for its lentiviral vector technology in USA
  • 01 Aug 2016 Preclinical trials in Peripheral nervous system diseases in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top